- Home
- EXEL vs DOGZ Comparison
EXEL vs DOGZ Comparison
Compare EXEL & DOGZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXEL
- DOGZ
- Stock Information
- Founded
- EXEL 1994
- DOGZ 2003
- Country
- EXEL United States
- DOGZ China
- Employees
- EXEL N/A
- DOGZ N/A
- Industry
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- DOGZ Miscellaneous manufacturing industries
- Sector
- EXEL Health Care
- DOGZ Consumer Discretionary
- Exchange
- EXEL Nasdaq
- DOGZ Nasdaq
- Market Cap
- EXEL 9.8B
- DOGZ N/A
- IPO Year
- EXEL 2000
- DOGZ 2017
- Fundamental
- Price
- EXEL $38.55
- DOGZ $16.68
- Analyst Decision
- EXEL Buy
- DOGZ
- Analyst Count
- EXEL 18
- DOGZ 0
- Target Price
- EXEL $37.59
- DOGZ N/A
- AVG Volume (30 Days)
- EXEL 2.4M
- DOGZ 125.3K
- Earning Date
- EXEL 05-09-2025
- DOGZ 05-16-2025
- Dividend Yield
- EXEL N/A
- DOGZ N/A
- EPS Growth
- EXEL 170.77
- DOGZ N/A
- EPS
- EXEL 1.76
- DOGZ N/A
- Revenue
- EXEL $2,168,701,000.00
- DOGZ $20,258,926.00
- Revenue This Year
- EXEL $5.78
- DOGZ N/A
- Revenue Next Year
- EXEL $10.94
- DOGZ N/A
- P/E Ratio
- EXEL $21.91
- DOGZ N/A
- Revenue Growth
- EXEL 18.50
- DOGZ 46.16
- 52 Week Low
- EXEL $20.14
- DOGZ $5.40
- 52 Week High
- EXEL $40.02
- DOGZ $58.50
- Technical
- Relative Strength Index (RSI)
- EXEL 63.64
- DOGZ 31.07
- Support Level
- EXEL $35.34
- DOGZ $16.40
- Resistance Level
- EXEL $37.67
- DOGZ $18.12
- Average True Range (ATR)
- EXEL 1.17
- DOGZ 2.47
- MACD
- EXEL 0.34
- DOGZ -0.19
- Stochastic Oscillator
- EXEL 96.71
- DOGZ 13.03
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.